Cancer Drugs Reimbursed with Limited Evidence on Overall Survival and Quality of Life: Do Follow-Up Studies Confirm Patient Benefits? G Chauca Strand, N Johansson, N Jakobsson, C Bonander, M Svensson Clinical drug investigation, 1-13, 2023 | 6 | 2023 |
Assessment of the clinical and cost-effectiveness evidence in the reimbursement decisions of new cancer drugs GC Strand, C Bonander, N Jakobsson, N Johansson, M Svensson ESMO open 7 (5), 100569, 2022 | 5 | 2022 |
Direct replication and additional sensitivity analyses for Altindag et al.(2022): A replication report from the Oslo Replication Games C Bonander, G Chauca Strand, N Jakobsson I4R Discussion Paper Series, 2023 | 1 | 2023 |
PCR221 Measurement and Analysis of Health-Related Quality of Life Data in Cancer Drug Trials: A Review of Post-Reimbursement Data M Svensson, GC Strand, C Bonander, N Johansson, N Jakobsson Value in Health 26 (6), S353, 2023 | | 2023 |